Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Ace who wrote (8795)	3/27/1998 8:50:00 PM
From: Keiko	Respond to of 14328

Ace, A few very interesting statements in the CDC report: (my emphasis ) "The sensitivity and specificity of RAPID assays are compatible to those of EIAs " "Using a rapid HIV test increases the number of HIV infected persons who learn they are infected, because most persons return for confirmatory results and counseling when they receive a preliminary positive result than when no result is provided until after confirmatory testing. " " When additional RAPID TESTS BECOME AVAILABLE for use in the United States, the USPHS will re-evaluate algorithms using specific combinations of TWO OR MORE rapid tests for screening and confirming HIV infections. " " In studies conducted outside the United States , specific combination of TWO OR MORE different rapid HIV assays have provided results as reliable as those from the EIA / Western Blot combination that is in widespread use." ( in the USA )

To: Ace who wrote (8795)	3/27/1998 9:56:00 PM
From: Keiko	Read Replies (1) \| Respond to of 14328

AIDS - Drug Cocktails Cause Steep Drop in Deaths New England Journal of Medicine .... nejm.org under " Original Articles ", click on Declining Morbidity & Mortality among Patients with HIV.

To: Ace who wrote (8795)	3/28/1998 5:35:00 PM
From: Ace	Read Replies (3) \| Respond to of 14328

Recently I attended a SH meeting on CLI Oncology. There offices are located in Jamestown, N.Y. specializing in research, development, and commercialization of diagnostics and therapeutics relating to metastatic cancer. They have made excellent progress in the past year on a technology platform diagnosing metastatic cancer in solid non- lymphoid tumors from a patented invention of Dr. Emilio Barbera- Guillem. Dr. Barbera is one of, if not the best researcher in his field. Awarded in Hepatology magazine in 1997 for Best article of the year and his article was on the July cover. Very impressive.... Trinity owns seven percent of CLIO so I feel it is important to bring to light on the thread. Look for a full report soon... ACE